R_y is: $-SCH_2CH(NH_2)C(O)OH$, $-SCH_2CH(NH_2)C(O)OH_3$, or $-SCH_2CH(NH_2)C(O)OC(CH_3)_3$;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, $-OCH_3$, C_{1-3} alkyl, $-CH_2OH$, $-CF_3$,


cyclopropyl, $-OCH_3$, -O(cyclopropyl) and/or $-NHCH_2CH_2OCH_3$;

each R_b is independently F, Cl, $-CH_3$, $-CH_2OH$, $-CF_3$, cyclopropyl, and/or $-OCH_3$;

y is zero, 1 or 2; and

z is 1 or 2.

[0009a] The present invention also provides a use of a first composition comprising one or more BCMA-targeting immuno-therapeutics and a second composition comprising one or more compounds represented by the structure of Formula (I):



(I)

and/or at least one salt thereof, wherein:


R_1 is $-CH_2CF_3$ or $-CH_2CH_2CF_3$;



R_2 is $-CH_2CF_3$, $-CH_2CH_2CF_3$, or $-CH_2CH_2CH_2CF_3$;

R_3 is H, $-CH_3$ or Rx;

R_4 is H or R_y;

R_x

is: $-CH_2OC(O)CH(CH_3)NH_2$, $-CH_2OC(O)CH(NH_2)CH(CH_3)_2$, $-CH_2OC(O)CH((CH(CH_3)_2)NHC(O)CH(NH_2)CH(CH_3)_2$, ,

, or ;

R_y is: $-SCH_2CH(NH_2)C(O)OH$, $-SCH_2CH(NH_2)C(O)OH_3$,

or $-SCH_2CH(NH_2)C(O)OC(CH_3)_3$;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, $-OCH_3$, C_{1-3} alkyl, $-CH_2OH$, $-CF_3$,

cyclopropyl, $-OCH_3$, -O(cyclopropyl) and/or $-NHCH_2CH_2OCH_3$;


each R_b is independently F, Cl, $-CH_3$, $-CH_2OH$, $-CF_3$, cyclopropyl, and/or $-OCH_3$;

y is zero, 1 or 2; and

z is 1 or 2,

in the manufacture of a medicament for treating, suppressing, or inhibiting a B-cell maturation antigen (BCMA)-related disorder or a disease associated with BCMA expression in a subject.

[0009b] The present invention also provides a use of a composition comprising one or more compounds represented by the structure of Formula (I):



(I)

and/or at least one salt thereof, wherein:

R_1 is $-CH_2CF_3$ or $-CH_2CH_2CF_3$;


R_2 is $-CH_2CF_3$, $-CH_2CH_2CF_3$, or $-CH_2CH_2CH_2CF_3$;

R_3 is H, $-CH_3$ or Rx;


R_4 is H or R_y;

R_x


is: $-CH_2OC(O)CH(CH_3)NH_2$, $-CH_2OC(O)CH(NH_2)CH(CH_3)_2$, $-CH_2OC(O)CH((CH(CH_3)_2)NHC(O)CH(NH_2)CH(CH_3)_2$,



,



, or



;

R_y is: $-SCH_2CH(NH_2)C(O)OH$, $-SCH_2CH(NH_2)C(O)OH_3$,

or $-SCH_2CH(NH_2)C(O)OC(CH_3)_3$;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, $-OCH_3$, C_{1-3} alkyl, $-CH_2OH$, $-CF_3$,

cyclopropyl, $-OCH_3$, -O(cyclopropyl) and/or $-NHCH_2CH_2OCH_3$;

each R_b is independently F, Cl, $-CH_3$, $-CH_2OH$, $-CF_3$, cyclopropyl, and/or $-OCH_3$;

y is zero, 1 or 2; and

z is 1 or 2

in the manufacture of a medicament for improving the efficacy of one or more BCMA-targeting immuno-therapeutics or for decreasing B-cell maturation antigen (BCMA) shedding from a cell in a subject.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010] The subject matter regarded as the invention is particularly pointed out and distinctly claimed in the concluding portion of the specification. The invention, however, both as to organization and method of operation, together with objects, features, and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanying drawings in which:

[0011] **Figure 1. Levels of cell-bound BCMA on multiple myeloma (MM) cells incubated with γ-secretase inhibitors (GSIs)**. U266 cells (MM cell line) were incubated with 0.3nM, 0.5nM, 1nM or 3nM of GSI (Compound 1, Compound 22, LY3039478 or PF3084014) for 24 hours, and BCMA levels were measured by flow cytometry.

[0012] **Figure 2A. Levels of soluble BCMA in cell media after incubation of multiple myeloma (MM) cells with Compound 22.** U266 cells (MM cell line) were incubated with 0.3nM, 1nM, 3nM and 10nM of Compound 22 for 24 hours, and levels of soluble BCMA were measured by ELISA.

[0013] **Figure 2B. Levels of soluble BCMA in cell media after incubation of multiple myeloma (MM) cells with LY3039478.** U266 cells (MM cell line) were incubated with 0.3nM, 1nM, 3nM and 10nM of LY3039478 for 24 hours, and levels of soluble BCMA were measured by ELISA.

[0014] **Figure 2C. Levels of soluble BCMA in cell media after incubation of multiple myeloma (MM) cells with Compound 1.** U266 cells (MM cell line) were incubated with 0.3nM, 1nM, 3nM and 10nM of Compound 1 for 24 hours, and levels of soluble BCMA were measured by ELISA.


[0015] **Figure 2D. Levels of soluble BCMA in cell media after incubation of multiple myeloma (MM) cells with PF3084014.** U266 cells (MM cell line) were incubated with 0.3nM, 1nM, 3nM and 10nM of PF3084014 for 24 hours, and BCMA levels were measured by ELISA.

[0016] **Figure 3. Levels of soluble BCMA in cell media after incubation of multiple myeloma (MM) cells with γ-secretase inhibitors (GSIs)**. U266 cells (MM cell line) were incubated with 0.3nM, 1nM, 3nM and 10nM of GSI (Compound 1, Compound 22, LY3039478 or PF3084014) for 24 hours, and BCMA levels were measured by ELISA.

[0017] **Figure 4A. Levels of BCMA in Lymphoma Cell Lines after treatment with the γ-secretase inhibitor (GSI), Compound 1.** Cells from five different lymphoma cell lines (SP49 (MCL with Notch4 GOF); Toledo (DLBCL); RC (Double Hit DLBCL – MYC, BCL2); SUDHL-4 (DLBCL); and SUDHL-6

CLAIMS

1. A composition comprising one or more B-cell maturation antigen (BCMA)-targeting immuno-therapeutics and one or more compounds represented by the structure of Formula (I):



(I)

and/or at least one salt thereof, wherein:




R_1 is $-CH_2CF_3$ or $-CH_2CH_2CF_3$;

R_2 is $-CH_2CF_3$, $-CH_2CH_2CF_3$, or $-CH_2CH_2CH_2CF_3$;

R_3 is H, $-CH_3$ or Rx;

R_4 is H or R_y;

R_x

is: $-CH_2OC(O)CH(CH_3)NH_2$, $-CH_2OC(O)CH(NH_2)CH(CH_3)_2$, $-CH_2OC(O)CH((CH_3)_2)NHC(O)CH(NH_2)CH(CH_3)_2$, , , or ;

R_y is: $-SCH_2CH(NH_2)C(O)OH$, $-SCH_2CH(NH_2)C(O)OH_3$,

or $-SCH_2CH(NH_2)C(O)OC(CH_3)_3$;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, $-OCH_3$, $C_{1\text{-}3}$ alkyl, $-CH_2OH$, $-CF_3$,


cyclopropyl, $-OCH_3$, -O(cyclopropyl) and/or $-NHCH_2CH_2OCH_3$;

each R_b is independently F, Cl, $-CH_3$, $-CH_2OH$, $-CF_3$, cyclopropyl, and/or $-OCH_3$;

y is zero, 1 or 2; and

z is 1 or 2.

2. The composition of claim 1, wherein said one or more compounds of Formula (I) are represented by the structure of Formula (II):




(II)

wherein

R_3 is H or $-CH_3$; and

y is zero or 1.

3. The composition of claim 2, wherein said one or more compounds are represented by the structure of Formula (IV):



(IV).

4. The composition of claim 1, wherein:

R_1 is $-CH_2CH_2CF_3$;


R_2 is $-CH_2CH_2CF_3$ or $-CH_2CH_2CH_2CF_3$; and

each R_a is independently Cl, C_{1-3} alkyl, $-CH_2OH$, $-CF_3$, cyclopropyl, $-OCH_3$, and/or -O(cyclopropyl).

5. The composition of claim 4, wherein: Ring A is phenyl; and R_3 is H.
6. The composition of claim 4, wherein: R_2 is $-CH_2CH_2CF_3$; and Ring A is phenyl.
7. The composition of claim 4, wherein:

R_2 is $-CH_2CH_2CF_3$; Ring A is phenyl; R_a is C_{1-3} alkyl or $-CH_2OH$; each R_b is independently F and/or Cl; and y is 1.

8. The composition of claim 4, wherein said one or more compounds are represented by the structure of Formula (V):



(V)

wherein:


R_3 is H or R_x.

9. The composition of claim 4, wherein said one or more compounds are selected from: (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (22); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-ethyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (23); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-isopropyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (24); (2R,3S)-N-(9-chloro-5-(3,4-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (25); (2R,3S)-N-(9-chloro-5-(3,5-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (26); (2R,3S)-N-((3S)-9-ethyl-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (27); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (28); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (29); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-9-(trifluoromethyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (30); (2R,3S)-N-((3S)-9-chloro-5-(3,5-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (31); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-9-(trifluoromethyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (32); (2R,3S)-N-((3S)-9-isopropyl-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (33); (2R,3S)-N-((3S)-9-(cyclopropyloxy)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (34); (2R,3S)-N-((3S)-9-(cyclopropyloxy)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (35); (2R,3S)-N-((3S)-9-

chloro-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl) succinamide (36); (2R,3S)-N-((3S)-9-methyl-2-oxo-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl) succinamide (37); (2R,3S)-N-((3S)-9-methyl-2-oxo-5-(3-(trifluoromethyl) phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl) succinamide (38); (2R,3S)-N-((3S)-9-chloro-5-(2-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (39); (2R,3S)-N-((3S)-5-(4-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (40); (2R,3S)-N-((3S)-9-chloro-5-(3-cyclopropylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (41); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (42); (2R,3S)-N-((3S)-5-(4-chlorophenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (43); (2R,3S)-N-((3S)-9-chloro-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (44); (2R,3S)-N-((3S)-5-(3-methylphenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (45); (2R,3S)-N-((3S)-5-(4-(hydroxymethyl)phenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (46); (2R,3S)-N-((3S)-5-(2-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (47); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (48); (2R,3S)-N-((3S)-9-methoxy-2-oxo-5-(5-(trifluoromethyl)-2-pyridinyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (49); (2R,3S)-N-((3S)-5-(5-chloro-2-pyridinyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (50); (2R,3S)-N-((3S)-5-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (51); (2R,3S)-N-((3S)-5-(4-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (52); (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-(hydroxymethyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (53); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-valinate (54); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-alaninate (55); S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-

1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteine (56); *tert*-butyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteinate (57); methyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl) hexanoyl)amino)-L-cysteinate (58); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl (4-(phosphonooxy)phenyl)acetate (59); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-valyl-L-valinate (60); and salts thereof.


10. The composition of claim 9, wherein said compound comprises:



(22).

11. The composition of any one of claims 1-10, wherein said BCMA-targeting immunotherapeutic comprises chimeric antigen receptor T (CAR-T) cells, a bispecific antibody, an antibody-drug conjugate, a tri-specific antibody, a trifunctional antibody, a chemically-linked Fab, or a bi-specific T-cell engager (BiTE).

12. Use of a first composition comprising one or more BCMA-targeting immuno-therapeutics and a second composition comprising one or more compounds represented by the structure of Formula (I):



(I)

and/or at least one salt thereof, wherein:




R_1 is $-CH_2CF_3$ or $-CH_2CH_2CF_3$;

R_2 is $-CH_2CF_3$, $-CH_2CH_2CF_3$, or $-CH_2CH_2CH_2CF_3$;

R_3 is H, -CH_3 or Rx;

R_4 is H or R_y;

R_x

is: -$CH_2OC(O)CH(CH_3)NH_2$, -$CH_2OC(O)CH(NH_2)CH(CH_3)_2$, -$CH_2OC(O)CH((CH_3)_2)NHC(O)CH(NH_2)CH(CH_3)_2$, , , or ;

R_y is: -$SCH_2CH(NH_2)C(O)OH$, -$SCH_2CH(NH_2)C(O)OH_3$,

or -$SCH_2CH(NH_2)C(O)OC(CH_3)_3$;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, -OCH_3, $C_{1\text{-}3}$ alkyl, -CH_2OH, -CF_3, cyclopropyl, -OCH_3, -O(cyclopropyl) and/or -$NHCH_2CH_2OCH_3$;


each R_b is independently F, Cl, -CH_3, -CH_2OH, -CF_3, cyclopropyl, and/or -OCH_3;

y is zero, 1 or 2; and

z is 1 or 2,

in the manufacture of a medicament for treating, suppressing, or inhibiting a B-cell maturation antigen (BCMA)-related disorder or a disease associated with BCMA expression in a subject.

13. The use of claim 12, wherein said BCMA-related disorder comprises a proliferative disease.
14. The use of claim 13, wherein said proliferative disease is a cancer, a pre-cancerous condition, or a benign proliferative disorder.
15. The use of claim 14, wherein said cancer comprises multiple myeloma, leukemia, lymphoma, a solid tumor or T-cell acute lymphoblastic leukemia (T-ALL).
16. Use of a composition comprising one or more compounds represented by the structure of Formula (I):



(I)

and/or at least one salt thereof, wherein:




R_1 is -CH_2CF_3 or -$CH_2CH_2CF_3$;

R_2 is -CH_2CF_3, -$CH_2CH_2CF_3$, or -$CH_2CH_2CH_2CF_3$;

R_3 is H, -CH_3 or Rx;

R_4 is H or R_y;

R_x

is: -$CH_2OC(O)CH(CH_3)NH_2$, -$CH_2OC(O)CH(NH_2)CH(CH_3)_2$, -$CH_2OC(O)CH((CH_3)_2)NHC(O)CH(NH_2)CH(CH_3)_2$, , , or ;

R_y is: -$SCH_2CH(NH_2)C(O)OH$, -$SCH_2CH(NH_2)C(O)OH_3$,

or -$SCH_2CH(NH_2)C(O)OC(CH_3)_3$;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, -OCH_3, $C_{1\text{-}3}$ alkyl, -CH_2OH, -CF_3, cyclopropyl, -OCH_3, -O(cyclopropyl) and/or -$NHCH_2CH_2OCH_3$;

each R_b is independently F, Cl, -CH_3, -CH_2OH, -CF_3, cyclopropyl, and/or -OCH_3;

y is zero, 1 or 2; and

z is 1 or 2

in the manufacture of a medicament for improving the efficacy of one or more BCMA-targeting immuno-therapeutics or for decreasing B-cell maturation antigen (BCMA) shedding from a cell in a subject.

17. The use of any one of claims 12-16, wherein said BCMA-targeting immunotherapeutic comprises chimeric antigen receptor T (CAR-T) cells, a bispecific antibody, an antibody-drug conjugate, a tri-specific antibody, a trifunctional antibody, chemically-linked Fab or a bi-specific T-cell engager (BiTE).


18. The use of any one of claims 12-17, wherein said one or more compounds represented by the structure of Formula (I) are selected from:

(2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (22); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-ethyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (23); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-isopropyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (24); (2R,3S)-N-(9-chloro-5-(3,4-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (25); (2R,3S)-N-(9-chloro-5-(3,5-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-

3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (26); (2R,3S)-N-((3S)-9-ethyl-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (27); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (28); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (29); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-9-(trifluoromethyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (30); (2R,3S)-N-((3S)-9-chloro-5-(3,5-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (31); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-9-(trifluoromethyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (32); (2R,3S)-N-((3S)-9-isopropyl-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (33); (2R,3S)-N-((3S)-9-(cyclopropyloxy)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (34); (2R,3S)-N-((3S)-9-(cyclopropyloxy)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (35); (2R,3S)-N-((3S)-9-chloro-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl) succinamide (36); (2R,3S)-N-((3S)-9-methyl-2-oxo-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl) succinamide (37); (2R,3S)-N-((3S)-9-methyl-2-oxo-5-(3-(trifluoromethyl) phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl) succinamide (38); (2R,3S)-N-((3S)-9-chloro-5-(2-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (39); (2R,3S)-N-((3S)-5-(4-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (40); (2R,3S)-N-((3S)-9-chloro-5-(3-cyclopropylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (41); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (42); (2R,3S)-N-((3S)-5-(4-chlorophenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (43); (2R,3S)-N-((3S)-9-chloro-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (44); (2R,3S)-N-((3S)-5-(3-methylphenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-

benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (45); (2R,3S)-N-((3S)-5-(4-(hydroxymethyl)phenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (46); (2R,3S)-N-((3S)-5-(2-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (47); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (48); (2R,3S)-N-((3S)-9-methoxy-2-oxo-5-(5-(trifluoromethyl)-2-pyridinyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (49); (2R,3S)-N-((3S)-5-(5-chloro-2-pyridinyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (50); (2R,3S)-N-((3S)-5-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (51); (2R,3S)-N-((3S)-5-(4-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (52); (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-(hydroxymethyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (53); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-valinate (54); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-alaninate (55); S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteine (56); *tert*-butyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteinate (57); methyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl) hexanoyl)amino)-L-cysteinate (58); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl (4-(phosphonooxy)phenyl)acetate (59); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-valyl-L-valinate (60); and salts thereof.

19. The use of claim 18, wherein said compound comprises:



(22).

20. The use of any one of claims 12-19, wherein said composition is formulated for intravenous or oral administration.